Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Pliant Therapeutics, Inc.

Pliant Therapeutics is a late-stage clinical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases

We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases and address the unmet needs of many patients.

Pliant’s co-founders include world-renowned researchers from the University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

Cormorant Asset Management

Cowen Healthcare Investments

Eventide

Novartis Institutes for Biomedical Research

Redmile Group

Agent Capital

Logos Capital

S-Cubed Capital

Schroder Adveq

Menlo Ventures

Pliant Therapeutics

Join members of #TeamPliant this week at the 2023 PFF Summit hosted by the Pulmonary Fibrosis Foundation. We are proud to be a Gold Sponsor of this event. Visit our booth and learn about BEACON-IPF, our clinical trial enrolling patients in IPF.  

#pffsummit

Today we presented our third quarter 2023 financials and provided a company update. Read about our 2023 accomplishments and 2024 milestones. https://lnkd.in/gAvSRpdb

Today we announced that we will participate in upcoming investor conferences hosted by Stifel Financial Corp., Evercore and Piper Sandler. See details on the fireside chats: https://lnkd.in/gqT439Hy

Teams presented three posters highlighting PLN-101095, a novel inhibitor of integrins αvβ8, and αvβ1, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. More on these presentations: https://lnkd.in/gXinxcdC #SITC2023 #SITC23

Looking forward to sharing our work with the oncology community this week at the Society for Immunotherapy of Cancer (SITC)'s Annual Meeting. View the abstracts: https://lnkd.in/eaPTMwXS
#SITC2023 #SITC23

Join a leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Learn more about Pliant’s culture, our active DEI initiatives, benefits and current openings: https://lnkd.in/gjPhTFf

#TeamPliant

Sunday is Global PSC Awareness Day. Our Plianteers will be joining the patient, caregiver and medical communities to acknowledge primary sclerosing cholangitis, a rare, progressive liver disease of unknown origin that occurs in all ages, genders, and races for which there are no current treatments. Learn more about this important day from PSC PARTNERS SEEKING A CURE: https://lnkd.in/gGVw3FSC   #PSCaware

Excited that our INTEGRIS-PSC Phase 2a data was selected for an oral late-breaker presentation at American Association for the Study of Liver Diseases (AASLD)’s The Liver Meeting® 2023. https://lnkd.in/gjBwk4fC

Pleased to welcome S. Mishima Gerhart as our Chief Regulatory Officer. Mishima is a recognized biopharmaceutical leader who brings global regulatory expertise and experience leading cross-functional teams across multiple therapeutic areas. Learn more about Mishima: https://lnkd.in/gGJYr_ve

We welcomed the Pulmonary Fibrosis Foundation and their Annual PFF Walk to the Bay Area where members of #TeamPliant came out in force to support a very worthy cause. This event highlights our shared commitment to raising awareness and funds to support the important patient and educational initiatives of the PFF. This year our Plianteers raised more than $20,000! Join us for a walk or come by our booth in Washington DC this weekend or in Dallas on October 21st! https://lnkd.in/gupva3M6

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue		57.05M -	41.82M 26.70%	7.57M 81.89%	9.69M 27.91%	1.58M 83.69%
cost of revenue						1.84M -
gross profit		57.05M -	41.82M 26.70%	7.57M 81.89%	9.69M 27.91%	-261K 102.69%
selling and marketing expenses
general and administrative expenses	6.50M -	10.93M 68.15%	17.27M 58.00%	27.56M 59.58%	39.95M 44.96%	57.93M 45.00%
selling general and administrative expenses	6.50M -	10.93M 68.15%	17.27M 58.00%	27.56M 59.58%	39.95M 44.96%	57.93M 45.00%
research and development expenses	24.41M -	47.35M 93.95%	66.19M 39.79%	77.55M 17.16%	96.94M 25.00%	125.96M 29.94%
other expenses	-49K -	-216K 340.82%	-366K 69.44%	-77.55M 21,088.25%
cost and expenses	30.91M -	58.28M 88.53%	83.46M 43.20%	27.56M 66.98%	136.88M 396.72%	185.72M 35.68%
operating expenses	30.91M -	58.28M 88.53%	83.46M 43.20%	27.56M 66.98%	136.88M 396.72%	183.88M 34.33%
interest expense				272K -	791K 190.81%	1.27M 60.18%
ebitda	-30.25M -	-118K 99.61%	-41.65M 35,192.37%	-19.99M 52.01%	-122.53M 513.08%	-182.30M 48.78%
operating income	-30.91M -	-1.23M 96.02%	-41.65M 3,283.02%	-19.99M 52.01%	-127.20M 536.45%	-184.15M 44.77%
depreciation and amortization	666K -	1.11M 67.12%	1.31M 17.70%	1.53M 17.18%	4.67M 204.23%	1.84M 60.58%
total other income expenses net	-49K -	600K 1,324.49%	112K 81.33%	272K 142.86%	3.88M 1,326.10%	22.81M 488.01%
income before tax	-30.28M -	-631K 97.92%	-41.53M 6,482.09%	-19.71M 52.53%	-123.32M 525.55%	-161.34M 30.83%
income tax expense	639K -	-816K 227.70%	-1.79M 119.12%	-1.81M 1.06%	-1.82M 0.89%
net income	-30.28M -	185K 100.61%	-39.74M 21,583.78%	-17.91M 54.95%	-121.50M 578.49%	-161.34M 32.79%
weighted average shs out	16.51M -	21.83M 32.22%	21.34M 2.22%	35.85M 67.94%	42.02M 17.21%	58.72M 39.75%
weighted average shs out dil	16.51M -	22.86M 38.47%	21.34M 6.64%	35.85M 67.94%	42.02M 17.21%	58.72M 39.75%
eps	-1.83 -	0.01 100.46%	-1.86 21,982.35%	-0.50 73.12%	-2.89 478%	-2.75 4.84%
epsdiluted	-1.83 -	0.01 100.44%	-1.86 23,062.96%	-0.50 73.12%	-2.89 478%	-2.75 4.84%

COM:PLIANTRX

Pliant Therapeutics

Last Close

12.85

22/11 21:00

Market Cap

669.01M

Beta: -

Volume Today

586.02K

Avg: -

Preview